GLP-1 & Incretin Science

The Endpoint Changes When the Patient Is Still Growing

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Adult obesity trials report percentage change in body weight. Trials in children and adolescents report percent change in body mass index instead, because a growing participant can gain height and weight simultaneously while their adiposity falls.

Key facts

Adult endpoint
Percent change in body weight
Paediatric endpoint
Percent change in BMI
Reason
Height is still increasing
Registry example
NCT06075667 primary outcome is BMI
Assessment standard
Growth reference percentiles
Known measurement problem
z-scores compress above the 95th percentile

Why body weight is the wrong endpoint in a growing person

An adolescent who grows several centimetres over a 68-week trial should gain some weight. Measuring success as weight reduction would penalise normal growth and reward its absence, which is the wrong incentive. BMI accounts for height, so it can fall while absolute weight holds steady or rises.

How obesity is defined differently in children

Adults are assessed against fixed BMI thresholds. Children are assessed against growth reference charts, because normal BMI varies substantially with age and sex through childhood. A child is classified by where they sit relative to a reference population of the same age and sex, commonly at or above the 95th percentile.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The measurement problem that follows

The natural way to express position on a growth chart is a z-score, the number of standard deviations from the reference mean. But the distribution is highly skewed at the upper end, so z-scores compress severely above the 95th percentile. A large change in actual BMI produces a small change in z-score. Wei and colleagues addressed exactly this in the Annals of Human Biology in 2020, publishing a method for calculating z-scores and percentiles above the 95th percentile.

Why that matters for trials specifically

Severe paediatric obesity sits in the compressed region. A trial reporting change in z-score would understate a real effect, and two trials using different handling of the upper tail would not be comparable. Reporting percent change in BMI avoids the compression entirely, which is why registered trials use it, NCT06075667 lists its primary outcome as percent change from baseline in body mass index.

What this means for reading a headline

A paediatric figure and an adult figure are not the same measurement. STEP TEENS reported a 16.1% mean change in BMI; adult semaglutide trials report percentage weight loss. Setting those numbers beside each other as though they described the same thing is a category error, and it happens routinely.

What this site is and is not describing

Registered clinical trials in defined paediatric populations, conducted under clinical supervision with ethics approval and specialist oversight. Nothing supplied here is a licensed medicine, is related to any of these compounds, or has any place in the care of a child.

Quick reference

Adult trialsPaediatric trials
Primary endpoint% change in body weight% change in BMI
Obesity defined byFixed BMI thresholdsGrowth reference percentile
Complication-z-score compression above 95th centile

Frequently asked questions

Why don't paediatric trials report weight loss?

Because participants are still growing. Measuring weight reduction would penalise normal growth and reward its absence.

What is z-score compression?

The BMI distribution is highly skewed at the top, so above the 95th percentile a large change in real BMI produces only a small change in z-score.

Can I compare a paediatric figure with an adult one?

No. One is percent change in BMI, the other percent change in body weight. They are different measurements.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.